LONDON, ONTARIO -- (MARKET WIRE) -- January 24, 2007 -- Critical Outcome Technologies Inc. (TSX VENTURE: COT), through its interest in DDP Therapeutics (formerly 6441513 Canada Inc.), has received promising preliminary results regarding in vitro drug resistance in lung cancer cell lines for the first 3 small cell lung cancer lead molecules. The lead molecules were discovered and optimized by Critical Outcome Technologies Inc. (COTI). COTI has a 10% equity interest in DDP Therapeutics (DDP).
